Kadence Bio key facts
as of Oct 2026- Developer of a small-molecule therapeutic designed to address significant unmet needs in sexual and mental well-being.
- Kadence Bio is valued at approximately $25.2M as of Oct 2026 (last reported valuation).
- It has raised $16.3M; the latest was Early Stage VC ($10.0M) in Jul 2025.
- Notable investors include Endless Frontier Labs, Dhuna Ventures, UCEA Capital Partners, Apeiron Capital, Alexander Luik — 20 tracked in total.
- Status: Privately Held (backing).
Kadence Bio's last reported valuation, Oct 2021. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch Kadence Bio: the Monday email on marks, rounds and moves
Kadence Bio funding rounds
No funding rounds for Kadence Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Kadence Bio
20+Kadence Bio valuation
Kadence Bio's last reported valuation was $25.2 million in Oct 2021. No priced round, secondary trade or fund mark has surfaced since.
Kadence Bio investors
20 investors are on record for Kadence Bio, including Endless Frontier Labs, Dhuna Ventures, UCEA Capital Partners and Apeiron Capital.
About Kadence Bio
Developer of a small-molecule therapeutic designed to address significant unmet needs in sexual and mental well-being. The company offers a clinical-stage treatment for premature ejaculation, enabling men experiencing challenges with sexual performance, mental health, and relationship wellbeing to access the first FDA-approved therapeutic option.
- Sector
- Healthcare
- HQ
- Sevenoaks, United Kingdom
- Founded
- 2021
- Employees
- 18
- Website
- kadencebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.